ArticleFrontiers in oncology2026
Identification of a fatty acid metabolism-related gene signature for prognostic prediction and immune microenvironment characterization in diffuse large B-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fatty acid metabolic reprogramming is critically implicated in tumorigenesis and progression. However, the role and prognostic significance of fatty acid metabolism-related genes (FMGs) in diffuse large B-cell lymphoma (DLBCL) remain largely unexplored. Methods: We analyzed transcriptomic data from the Gene Expression Omnibus (GEO) database to identify key prognostic FMGs. Through an integrative machine learning pipeline, we developed a prognostic signature termed the FAMscore. The association of the FAMscore with tumor immunity was assessed. Furthermore, we validated the dysregulation of multiple FMGs using quantitative real-time PCR and single-cell RNA sequencing data. Among these FMGs, we further investigated the role of CPT1A in DLBCL cell proliferation and apoptosis. Results: The FAMscore effectively distinguished between high- and low-risk DLBCL patients and served as an independent prognostic factor. A higher FAMscore was associated with poorer overall survival (OS). A nomogram integrating the cell-of-origin (COO) subtype, the International Prognostic Index (IPI) score, and the FAMscore was developed and demonstrated reliable predictive performance. Tumors in the high-FAMscore group exhibited higher tumor purity and an immune infiltration profile conducive to an immunosuppressive microenvironment. Functional assays revealed that knockdown of CPT1A significantly inhibited DLBCL cell proliferation and induced apoptosis. Conclusions: Our study highlights fatty acid metabolism as a key prognostic indicator and immune regulator in DLBCL. These findings advance the framework for personalized treatment strategies in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.